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Background. B1 B cells are believed to be a unique lineage with a distinct developmental pathway, function and activation
requirement. How this lineage is genetically determined remained largely obscure. Methods and Principal Findings. Using
the Siglecg-deficient mice with a knockin of green-fluorescent protein encoding sequence, we show here that, although the
Siglecg gene is broadly expressed at high levels in all stages and/or lineages of B cells tested and at lower levels in other
lineages, its deletion selectively expanded the B1a B cell lineages, including the frequency of the B1 cell progenitor in the bone
marrow and the number of B1a cells in the peritoneal cavity, by postnatal expansion. The expansion of B1a B cells in the
peritoneal correlated with enhanced activation of NFkB and was ablated by an IKK inhibitor. Conclusion and Significance.
Our data revealed a critical role for Siglec G-NFkB pathway in regulating B1a B cell lineage. These data lead to a novel model of
B1a lineage development that explains a large array of genetic data in this field.
Citation: Ding C, Liu Y, Wang Y, Park BK, Wang C-Y, et al (2007) Siglecg Limits the Size of B1a B Cell Lineage by Down-Regulating NFkB Activation. PLoS
ONE 2(10): e997. doi:10.1371/journal.pone.0000997
INTRODUCTION
An important choice a B cell makes is whether to become B1a B
cells that produce poly-reactive natural IgM, B1b cells that make
adaptive IgM response, or conventional B2 B cells that primarily
mediate T-dependent adaptive immunity [1,2,3]. While extensive
studies have revealed critical roles for the B cell receptor (BCR)
recognition, such as its self-reactivity, in determining the lineage
choices [4,5], accumulating evidence indicate that the size of B1 B
cells are likely regulated by other factors. For instance, naturally
occurring mutations of Ptpn6 which encodes Shp1 leads to
dramatic increase of the B1a B cell compartment [6]. Recent
studies using lineage-specific deletion of the Ptpn6 gene demon-
strated a B cell-intrinsic function of SHP1 in limiting the size of the
B1a B cells [7]. On the other hand, targeted mutations of C-Rel
and NFkB1, two components of NFkB complex, leads to
a significant reduction of the B1 B cells [8]. How these
intracellular signaling pathways are used by cell surface molecular
interactions to regulate the size of B1 B cell lineage is largely
unknown. In particular, targeted mutation of genes encoding
several potential membrane proteins that can associate with SHP1,
including those of CD72 and CD22, did not substantially impact
the development of B1 B cell lineage [9,10,11,12].
Of particular interest are members of the sialic acid-binding,
immunoglobulin-like lectin family, or Siglec, many of which have
ITIM Motifs for association with SHP1 [13]. Several members of
the families, including Siglec 10, the human orthologue of Siglec
G, have been demonstrated to be associated with SHP1 [14,15].
While targeted mutation of Sialoadhesin reduced IgM level, this
mutation does not appear to affect the B1 B cell lineage [16].
Siglec G and its human orthologue Siglec 10 appears to have
several alternative splicing variants [17,18] [14,15]. All variants,
however, shared the same cytoplasmic domain with the ITIM
motif capable of interacting with SHP-1, which was known to be
a negative regulator for B1B cell lineages. Since the function and
expression of Siglec G have not been characterized in detail, we
produced Siglec G-deficient mice with a knockin of GFP open-
reading frame to report its expression. Our results revealed that
Siglec G is expressed at high levels at essentially all stages of B cell
development and significant but reduced levels in other cell
lineages. Importantly, targeted mutation of the Siglec G gene
dramatically expanded the B1a B cell lineages postnatally, by
increasing NFkB activation. Our data revealed Siglec G is
a molecular checkpoint that limits the postnatal expansion of
B1a B cells by repressing NFkB activation.
RESULTS
GFP-knock-in mice reveal wide-spread expression of
Siglecg in multiple lineages
Previous studies using flow cytometry have suggested that Siglec
10 may be expressed in subsets of human leukocytes including
eosinophils, monocytes and a minor population of natural killer-
like cells [18]. Because of the alternative splicing, it is unclear
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investigate the cell lineage in which the Siglecg locus is active while
studying the function of the Siglecg in vivo, we replaced essentially
all coding exons of the Siglecg sequence with a GFP coding
sequence, as diagramed in Supplemental Fig. S1A. The genomic
DNA clones were isolated from C57BL/6j DNA library for
homologous recombination in the ES cells of C57BL/6 origin.
The neomycin-resistant ES cell clones were screened for
homologous recombination. The clone that was ultimately used
for blastocyte injection was shown in Fig. S1B. The chimera mice
were continuously bred in B6 background and the offspring shows
typical Mendalian distribution of +/+, +/2 and 2/2 genotypes
(data not shown). The deletion of the endogenous Siglecg genomic
sequence is shown in Fig. S1C.
Since the GFP cDNA is fused into exon 2 of the Siglecg gene, its
expression is controlled by the regulatory elements of the Siglecg
locus. We therefore used the expression of GFP to report
transcription of Siglecg. The gene dose effects are measured by
comparing the +/2 and 2/2 littermates.
The hematopoeitic cells in the bone marrow were identified as
FLSK subset, which are Lin
2Flt2
2Sca1
+and c-Kit
+[19]. The size
of the HSC does not differ among the littermates of the three
genotypes (Table 1). Nevertheless, the locus is transcribed in the
HSC, albeit at lower levels (Fig. 1A). The Pre-Pro/Pro B cells, as
defined by IgM
2B220
loCD43
+ [20,21], expressed higher levels of
the Siglecg transcripts (Fig. 1B). Among the spleen cells, the B cells
(B220
+) expressed the highest levels of Siglecg (Fig. 1C). However,
significant levels were also detected in DC (CD11c
+), myeloid cells
(CD11b
+), and to a less extent, T cells (CD3
+) (Fig. 1C). We further
analyzed the GFP levels among the major known B cell subsets. As
shown in Fig. 1D, essentially all known subsets expressed high
levels of Siglecg. Interestingly, heterogeneity of GFP levels was
found at all subsets of hematopoeitic cells studied, starting at the
HSC.
Taken together, our data demonstrated that the Siglecg locus is
transcribed in essentially all the major cell types in the
hematopoeitic cell types analyzed, although B cells, as a group,
seem to have the highest levels.
Targeted mutation of Siglecg leads to preferential
expansion of B1a B cells in the peritoneal cavity
Given the wide-spread expression of Siglecg, we determined
whether targeted mutation of the gene affects the development
of different compartments of the hematopoeitic cells by flow
cytometry. As shown in table 1, the compositions of the major
hematopoeitic subsets, including HSC, T cells, myeloid cells,
dendritic cells and different stages of B cells, were comparable
between the WT and the mutant mice. Surprisingly, we have
observed a 5-fold increase in the size of B1a cells in the peritoneal,
although the number of B1b subset was unchanged (Fig. 2A). The
number of B1a cells in the spleen, however, did not differ in adult
mice (Fig. 2B lower panel and table 1), although a two fold
expansion of spleen B1 B cells can be observed at two weeks
(Fig. 2B, upper panel).
Corresponding to the expansion of the B1a cells, the levels of
serum IgM increased by 5-10 fold (Fig. 2C). With exception of
IgG1, which is reduced by approximately 2-fold, the levels of other
Ig isotypes was unaffected by Siglecg deletion. To determine
whether deletion of Siglecg affects adaptive B cell responses, we
immunized the WT and Siglecg-deficient mice with OVA and
determined the antibody levels at one and two weeks after
immunization. As shown in Fig. 2D, the antibody response was
essentially unaffected by the Siglecg deletion.
Table 1. Selective expansion of B1a cells in the peritoneal of the Siglecg-deficient mice.
..................................................................................................................................................
cell population % of cells
siglecg
2/2 siglecg
+/+
Bone marrow HSC (FLSK) cells 0.085 6 0.05 0.094 6 0.04
Prepro/Pro B (CD43
+B220
+IgM
2) 2.45 6 0.30 2.81 6 0.46
PreB (fr. D) (CD43
2B220
+IgMlowIgD
low) 2.436 0.39 2.15 6 0.25
New B (CD43
2B220
+IgM
hiIgD
low) 1.36 6 0.22 1.22 6 0.22
Mature B (CD43
2B220
+IgM
hiIgD
hi) 1.07 6 0.11 1.30 6 0.19
Dendritic cells (CD11c
+) 1.23 6 0.09 1.19 6 0.10
cell number ( 610
26)
Spleen Total B (B220
+) 42.45 6 8.55 43.99 6 10.50
FO B (B220
+CD23
hiCD21
hi) 29.49 6 3.62 32.16 6 2.66
MZ B (B220
+CD23
lowCD2
hi) 3.22 6 0.60 2.55 6 0.55
T1 (B220
+AA4.1
+CD23
lowIgM
hi) 6.07 6 2.88 4.55 6 1.98
T2 (B220
+AA4.1
+CD23
hiIgM
hi) 4.05 6 1.77 4.89 6 2.12
B-1a (B220
+CD43
+CD5
+) 1.97 6 0.36 2.12 6 0.39
Macrophages (CD11b
+) 4.97 6 2.02 5.55 6 1.99
Dendritic cells (CD11c
+) 1.32 6 0.22 1.16 6 0.33
T cells (CD3
+) 23.02 6 6.99 27.60 6 8.60
Peritoneal cavity B-1a (B220
+CD11b
+CD5
+) 2.41 6 0.51 0.46 6 0.16
B-1b (B220
+CD11b
+CD5
2) 1.07 6 0.25 1.25 6 0.33
T cells (CD3
+) 0.97 6 0.11 1.11 6 0.29
The cell subsets were phenotyped as described [27]. For BM HSC cells, N=3. For spleen and peritoneal cavity T cells, N=6. For all other cells, N=12.
doi:10.1371/journal.pone.0000997.t001
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Siglecg Controls B1a Lineage
PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e997Postnatal expansion of B1a progenitors in the
Siglecg
2/2 mice
It is generally believed that the B1a progenitors give rise to mature
B1a cells during fetal development and that self-renewal of the B1a
cells after birth explains the long-life persistence of the B1a lineage
[3]. More recently, a low number of B1a progenitor cells were
identified in mature bone marrow [22]. In order to explain the
drastic difference in the number of B1a cells in the peritoneal
cavity, we carried out BrdU labeling to determine the proliferation
of the B1a cells. As shown in Fig. S2, at two weeks, when
a significant difference was observed in the % of B1a B cells found
in the spleen, the rate of BrdU incorporation was the same in the
two groups. Conversely, at 10 weeks, when no difference in the
B1a subsets was observed in the spleen, there appeared to be
a higher rate of BrdU incorporation in the siglecg-deficient mice.
Furthermore, in the peritoneal cavity, where a dramatic difference
of the number of B1a cells were found, the rate of BrdU
incorporation was essentially identical. Thus, while our data did
not rule out the possibility that Siglecg may regulate B1a
proliferation in specific locations, such function does not account
for the differential accumulation of B1a cells in the Siglecg-deficient
mice. Likewise, the % of Annexin V
+ cells was also comparable
(Fig. S3). Thus, neither increased self-renewal nor decreased
apoptosis of mature B1a cells explain the expansion of the B1a
compartment.
To explore the possibility that increased number of B1a cells
may be due to the expansion of the B1 progenitors, we compared
the number of the progenitors in the fetal liver and adult bone
marrow. The Lin
2AA4.1
+ liver and bone marrow mononuclear
cells can be further divided into 4 subsets by their expression of
B220 and CD19. Among them, CD19
+ B220
lo subsets are
considered the B1a progenitors, while the CD19
2B220
hi subsets
are regarded as the B2 progenitors [22]. As shown in Fig. 3A, the
number of B1a progenitors in the E16.5–E17 fetal livers was
unaffected by Siglecg mutation. Likewise, the number of B1a
progenitor in the newborn livers was also similar between WT and
mutant mice (Fig. 3B). In contrast, the number of B1 progenitors
was expanded by 4-fold in the bone marrow of adult Siglecg-
deficient mice, in comparison to what was found in the WT
Figure 1. Transcription of the Siglecg locus as determined by the expression of GFP which was used to replace the coding sequence of Siglecg.
Red, WT; green heterozygous; blue, homozygous. A. Low levels of GFP expression among the hematopoeitic cells. The left panel shows the profiles of
Lin
2Flt2
2Sca-1
+C-Kit
+ hematopoeitic stem cells (HSC), while the right panel depicts the GFP intensity of the gated HSC. B. Expression of the Siglecg
locus in the pre-Pro/Pro B cells. As in A, except that the IgM
2CD43
+B220
lo cells were depicted. C. Transcription of the Siglecg locus among splenic B
cells (B220
+), myeloid cells (CD11b
+), dendritic cells (CD11c
+) and T cells (CD3
+). The top panel shows summary data, while the lower panels show
representative FACS profiles. D. The Siglecg locus is actively transcribed at all stage/lineages of B cells, as in C. Data shown in this Figure represents 2
mice per group, and has been repeated twice.
doi:10.1371/journal.pone.0000997.g001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e997littermates (Fig. 3C). In either compartment, the B2 progenitors
were not affected by siglecg mutation (Fig. 3A–C).
To determine whether the adult bone marrow from the siglecg-
deficient mice have increased tendency to reconstitute the B1a
compartment, we mixed equal numbers of total bone marrow cells
from Siglecg
+/+ (CD45.1) and the Siglecg
2/2 (CD45.2) mice, and
adoptively transferred them into lethally irradiated WT or
Siglecg
2/2 host. Unlike the mice with B cell-specific deletion of
Ptpn6 [7], no expansion of B1a cells was found in the bone marrow
was found in the Siglecg
2/2 mice (Fig. S4), therefore no effort was
made to delete the B1a cells from bone marrow. Thirteen weeks
after bone marrow transplantation, the bone marrow, peritoneal
cavity and spleen were harvested and analyzed by flow cytometry.
As shown in Fig. 4A, regardless of the recipient genotypes, the
Siglecg
2/2 bone marrow were more efficient in reconstituting the B
cell compartment, including Pre-ProB/Pro and Pre/new B cells,
and the total number of B cells. In contrast, bone marrows from
the two genotypes were comparably efficient in reconstituting the
myeloid compartment.
Importantly, in the peritoneal cavity, the number of Siglecg
2/2
B1a cells was 2–3 fold more abundant than that from the WT
bone marrow, while the number total B cells were not significantly
different (Fig. 4A lower panel and Fig. 4B). In addition to the
difference in the total number, an interesting difference in the cell
surface markers was also observed. Thus, the majority of the B1a
cells derived from WT bone marrow expressed high CD5,
essentially all of the B1a cells from the mutant bone marrow
exhibited low levels of CD5. The increased number of progenitor
cells in the adult bone marrow, but not in fetal liver, and over-
presentation of mutant B1a cells in the peritoneal cavity strongly
suggests that the expansion of the B1a cells in the peritoneal cavity
of the Siglecg
2/2 mice was due to postnatal expansion of the B1a
Figure 2. Selective expansion of peritoneal cavity B1a cells in mice with targeted mutation of the Siglecg gene. A. Expansion of B1a, but not B1b
subsets. The top panel shows the profile of B cells among peritoneal lavages of 10 weeks old mutant and age-matched WT controls, while the lower
panel shows summary data involving 10 mice per group. This experiment has been repeated 5 times involving a total of 10–12 mice per group. C.
Serum concentration of different isotypes of Ig, note substantial increase of IgM and decrease of IgG1 in the mutant mice. Data shown in the lower
panels are Means+SEM, with 20 mice per group. D. Adaptive B cell response in WT and the Siglecg-deficient mice. The WT and Siglecg-deficient mice
were immunized with 200 mg of OVA in complete Freunds’ adjuvants (CFA) on day 0, boosted with the same amounts of OVA on day 7. Sera were
collected on day 1, 7 and 14 for measurement of anti-OVA antibodies by ELISA using the OVA-coated plate. Data shown are means+SEM of optical
density, n=6. Sera were used at 1:500 dilutions for the ELISA.
doi:10.1371/journal.pone.0000997.g002
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Interestingly, unlike the peritoneal cavity, the number of B1a cells
in the spleen is mainly derived from the WT donor (Fig. S5). Such
phenotype is reminiscent of a recently reported phenotype
associated with SHP-1 mutation in the B cell compartment [7].
Activation of NFkB is essential for the expansion of
the B1a compartment in the peritoneal cavity of the
Siglecg
2/2 mice
We compared ex vivo WT and Siglecg-deficient peritoneal cavity
cells for activation of a number of signal transduction pathways,
including phosphorylation of Akt, Stat 3, Stat 5, P38, Erk and
JNK. Our extensive analyses fail to reveal a significant difference
between the WT and mutant cells (Data not shown). Since
mutation of Ptpn6, which associate with Siglecg orthologue Siglec
10, enhanced NFkB activation and expanded B1a compartment
[6], and since mice with targeted mutation of components in
NFkB pathway show selective reduction of B1a B cell compart-
ment [8], we focused on the potential impact of Siglecg deletion on
NFkB activation. As shown in Fig. 5A, ex vivo peritoneal lavage
from Siglecg-deficient mice show greatly increased IkBa phosphor-
ylation in the cytosol and nuclear accumulation of P65, as
demonstrated by Western blot (Fig. 5A). This corresponds to
greater binding to NFkB probe as revealed by mobility shift assays
(Fig. 5B). Furthermore, the increased NFkB function was revealed
by luciferase assay when the peritoneal cells from WT and Siglecg-
deficient mice were compared (Fig. 5C).
The increased IkBa phosphorylation indicated enhanced IKK
activity in the B1a cells from the Siglecg
2/2 peritoneal cavity. To
determine whether the activation of NFkB is essential for the
expansion of the B1a compartment, we treated the 5-days old
Siglecg-deficient mice with IkB kinase complex (IKK) inhibitor VI,
which we have demonstrated to work efficiently in the mice [23].
As shown in Fig. 6A, consecutive treatment resulted in greatly
decreased IkBa phosphorylation and nuclear P65 accumulation.
Importantly, the percentage and number of B1a cells in the
peritoneal cavity was reduced by 3–4 folds in the treated group. In
contrast, despite effective inhibition of IKK, the number of B1a
cells in the spleen was unaffected by the inhibitor (Fig. 6B). These
Figure 3. Postnatal expansion of B1a but not B2 progenitor cells. A. Progenitor cells from fetal liver. B. Progenitor cells from new born liver cells. C.
Percentage of B1 (CD19
+B220
lo) and B2 (CD19
2B220
hi). Data shown in A involve 2 WT and 2 mutant mice per group. Data shown in B involve 3 WT
and 4 mutant mice per group. Similar levels were found in 12 heterozygous littermates. C. As in A, except 10 week old bone marrow were analyzed.
N=7.
doi:10.1371/journal.pone.0000997.g003
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selective expansion of the B1a cells in the peritoneal cavity of the
Siglecg
2/2 mice.
DISCUSSION
A long-standing observation in immunology is the preferential
accumulation of B1a B cell in the peritoneal cavity. Given the
importance of the B1a B cells in innate immunity and
autoimmune diseases [1,2,3], the mechanisms that determine the
size of B1a B cell subsets in the locality are of great interest. Using
mice with targeted mutation of the Siglecg gene, we demonstrate
that Siglecg controls B1 B cell expansion in the peritoneal cavity by
repressing NFkB activation.
Siglecg controls a checkpoint for peritoneal B1a B
cell expansion
We have observed mice with targeted mutation of Siglecg that had
a 5–10 fold increase in serum IgM, while those of most other Ig
isotypes were roughly normal. In search for a cellular basis for the
over-production of IgM, we uncovered the dramatic expansion of
the B1 B cells in the peritoneal cavity. Of the two subsets of B1 B
cells in the cavity, the expansion is limited to the CD11b
+ B1a
subsets. Moreover, while the expansion of the B1a B cells in the
peritoneal cavity were observed throughout the study, the
expansion of the B1 B cells in the spleen is only transient,
observable at 2 weeks but not 10 week.
Since no reagent is currently available to study the protein
expression for mouse Siglecg, we used a GFP knockin transgenic
line to determine the expression of Siglecg. Our data indicated that
while cells among B cell lineage had the highest levels of Siglecg
expression, essentially all major subsets of hematopoeitic cells
examined, including T cells, DC, and monocytes show active
transcription of the locus. Despite the wide-spread expression of
the gene, the impact of Siglecg deletion appear to be limited to the
B1a B cells in the peritoneal cavity, although a smaller expansion
of the B1a B cells in the spleen can be observed at 2 weeks of age.
While our manuscript was in preparation, Hoffmann et al. [24]
reported a Siglecg-deficient mouse prepared with ES cells from the
BALB/c. While they observed expansion of B1a cells in the spleen
Figure 4. Siglecg-deficient bone marrow cells have competitive advantages in reconstituting bone marrow B cell lineage and peritoneal B1a
subsets in lethally irradiated recipients. The WT (CD45.1) and Siglecg
2/2 (CD45.2) bone marrow cells were mixed at a 1:1 ratio and used to
reconstitute the lethally irradiated mice, 13 weeks later, the mice were sacrificed for analysis. The bone marrow and peritoneal lavages were analyzed
by flow cytometry for reconstitution by WT and mutant bone marrow cells. A. Summary data showing the contribution of WT (open bars) and mutant
bone marrow cells (filled bars). The cell subsets in bone marrow include total B cells (B220
+), Pre-pro/Pro B (CD43
+B220
losIgM
2) and pre/new B
(CD43
2B220
+IgM
low-highIgD
low). The lower panel summarizes the total B cells and B1a B cells in the peritoneal lavages. Data shown are mean+SEM,
N=5. B. Representative profiles depicting the relative contribution of WT (CD45.1) and Siglecg-deficient (CD45.2) cells to the B1a compartment. C.
Representative profiles depicting distinct profile of WT and Siglecg-deficient B1a cells.
doi:10.1371/journal.pone.0000997.g004
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more selective. The difference in background genes between the
two strains of mice may account for the difference.
Postnatal expansion of B1a progenitors and
expansion of B1 B cells in the Siglecg-deficient mice
While the B1a B cells are generally believed to have been
produced from progenitors in fetal liver [3], recent studies
identified B1a progenitors in adult bone marrow [22] [25].
Therefore, the expansion of the B1a B cell compartment can
theoretically be attributed to either increased fetal production or
postnatal production. Our analysis of adult progenitor cells in the
bone marrow and fetal livers indicated a substantial increase in the
B1a B progenitors in the bone marrow, but not in the fetal or new
born liver. Consistent with the increased B1a B progenitor cells,
the Siglecg-deficient bone marrow are more efficient in constituting
the B1a B cells. These data, together with the fact that neither
increased proliferation nor decreased apoptosis explains the
expansion of B1a B cells in the peritoneal cavity, supports the
notion that postnatal expansion of the B1a compartment is
responsible for the expansion of B1a cells in the Siglecg
2/2mice.
Therefore, our data demonstrate a novel function of Siglecg in
regulating postnatal expansion of the B1a compartment. It
remains to be determined as to whether the expansion is intrinsic
to genetic defects in the precursor cells, or due to Siglecg defects in
other cell types.
It is worth pointing out that although the number of progenitors
for B2 cells were not increased, the siglecg-deficient bone marrow
was more efficient in reconstituting B cells than the WT bone
marrow when they were mixed with WT bone marrow cells.
These data suggest that in addition to the number of B1 B
progenitors, Siglecg exerts a general repressive effect on the
differentiation of the B cell compartment. Such requirement,
however, seems to be reflected in competition with progenitor cells
from the WT host, but not with other cell lineage, as the relative
number of B cells are the same when the Siglecg-deficient mice
were analyzed.
Siglecg is a negative regulator of NFkB activity in
peritoneal B cells: similarity with Shp1
Our comparison between WT and Siglecg-deficient ex vivo
peritoneal lavage revealed that activation of a number of signaling
pathways, including AKT, STAT, Erk, P38 and JNK was not
affected by the mutation (data not shown). In contrast, a profound
activation of NFkB was observed in the peritoneal lavages from
the Siglecg-deficient mice in comparison to that from WT mice, as
indicated by increased phosphorylation of IkB, nuclear localiza-
tion of P65, increasing mobility shift of the NFkB probe and
increased promoter activity when the NFkB reporter constructs
were used to transfect the peritoneal lavage cells. Since the
activation correlates with the IkB phosporlation, it is likely that the
conical NFkB pathway is being activated. Moreover, since the
IKK is responsible for IkB phosphorylation, we used the IKK
inhibitor VI to block NFkB activation in order to study the
significance of this activation in B1a cell expansion in the
peritoneal cavity. Our data clearly demonstrated that activation
of NFkB is responsible for the expansion of the B1a cells in the
peritoneal cavity. Recently, Hoffmann et al. reported that mutant
B cells display increased Ca
2+ signaling in responses to several
stimuli in vitro [24]. Since it is unclear if these stimuli are
responsible for the B1a expansion in vivo, the significance of the
enhanced Ca
2+ response remains to be demonstrated.
Interestingly, despite the significant effect of the IKK inhibitor
for spleen cells, no increase in the spleen B1a B cells were
observed. These data clearly indicated that expansion of B1a B
cells in the peritoneal cavity uses a mechanism that is not
employed to maintain the number of spleen B1a B cells. The
selective expansion of B1a B cells from the mutant peritoneal
cavity suggests that the expansion requires both unique checkpoint
in the specific cell lineage and specific stimuli in the peritoneal
cavity. Moreover, we have observed no effect of IIKK inhibitor on
BrdU incorporation in B1a cells (data not shown). However, since
our data also indicated that the expansion cannot be demonstrated
by BrdU incorporation (Fig. S2), the cellular basis for the increase
remains to be determined.
Recently, Rajewsky and colleagues demonstrated that targeted
mutation of Shp1 in the B cell lineage causes expansion of B1a B
cells in the peritoneal cavity [7]. Remarkable similarity can be
found between the germline mutation of the Siglecg and B-cell
specific deletion of Ptpn6. Firstly, in terms of lineage size, the
impact of mutation is limited within B1a B cells in the peritoneal
cavity. Secondly, the expansion of B1a subsets is due to the
postnatal expansion of B1a cells. Thirdly, in bone marrow chimera
Figure 5. Siglec
2/2 peritoneal cavity lavage cells have increased
NFkB activity. A. Western blot analysis of cytosolic total and
phorsphorylated IkBa (upper panels) and nuclear P65, using the
amounts of SP1 as loading control (lower panels). B. EMSA analysis of
nuclear NFkB activity. Nuclear lysates from WT (+/+) or knockout
peritoneal lavages were prepared and tested for retardation of
32P NFkB
probe. The specificity of the gel retardation was confirmed by super-
shift with anti-P50 or P65 antibodies. C. Luciferase activity of peritoneal
cells from WT and knockout mice. Data shown in this figure have been
repeated twice.
doi:10.1371/journal.pone.0000997.g005
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reconstituting the peritoneal B1a B cells, while displaying
a disadvantage in constituting spleen B1a B cell compartment.
These similarities in functional defects raise the possibility that the
gene has a similar function within B cell compartment. Since
Siglc10, the Siglec G orthologue in human, has been shown to be
associated with Shp1[14,15], the simplest hypothesis is that Shp1
works down-stream of Siglec G in limiting the controlled
expansion of B1a subset. This hypothesis has the potential to
unify observations made from mice with genetic defects of Siglecg,
Ptpn6, and NFkB1 and C-rel. Since mutation of Siglecg increases the
titer of anti-DNA antibodies [24] and since deletion of Shp1 in B
cells causes autoimmune diseases [7], the balance of the Siglecg
signaling will likely be important in the proper tuning of the B1a
function in innate immunity against infection vs. autoimmune side
effect. Given recent advances in pharmaceutical targeting of the
NFkB pathway [23], our study suggests a new approach in
selective tuning of innate immunity and autoimmunity.
MATERIALS AND METHODS
Generation of Siglecg
2/2GFP
+/+ mice using C57BL/6
ES cells
The production of the Siglecg
2/2GFP
+/+ mice is carried out by the
Ingenious Research Laboratory, Inc. (Long Island, New York)
under a research contract. Detail information is provided by
Fig. S1. Briefly, a ,9.8 kb region used to construct the targeting
vector was first sub cloned from a positively identified BAC clone
using a homologous recombination-based technique. The region
was designed such that the short homology arm (SA) extends
1.8 kb 39 to exon 11. The long homology arm (LA) ends in exon 2
just before the ATG and is ,8.8 kb long. The GFP/Neo cassette
(Neo is flanked by both loxP and FRT sites) is inserted before the
ATG of Exon 2 and replaces ,5 kb of the gene sequence
including exons 3–11.
Ten micrograms of the targeting vector was linearized by AscI
and then transfected by electroporation of iTL C57/Bl6
embryonic stem cells. After selection in G418, surviving clones
were expanded for PCR analysis to identify recombinant ES
clones. Primers, A1, 2 and 3 were designed downstream (39) to the
short homology arm (SA) outside the region used to generate the
targeting construct. PCR reactions using A1, 2 or 3 with the N1
primer at the 59 end of the Neo cassette amplify 2.0, 2.0 and 2.1kb
fragments respectively. The control PCR reaction was done using
AT1 and AT2, which is at the 59 end of the SA inside the region
used to create the targeting construct. This amplifies a band of
1.7 kb. As shown in Fig. S1B, Individual clone was screened with
A1/N1, A2/N1 and A3/N1 primers. ES clone #361 was
identified as a recombinant clone and injected into BALB/c
blastcytes. The chimera mice were bred to B6 mice to obtain F1
mice, which were intercrossed to generate Siglecg
2/2GFP
+/+ mice,
and their WT and heterozygous littermates.
Figure 6. IKK inhibitor treatment decreased B-1a cells in peritoneal cavity but not spleen. (A). Efficacy of the treatment in reducing IKK activity
among total spleen cells as revealed by IkBa phosphorylation in the cytosol (upper panel) P65 accumulation in the nuclei (lower panel) of spleen cells
from treated or control mice. B. The impact of inhibiting the IKK on peritoneal B1a subsets. Data shown are means+SEM involving 5–6 mice per
group.
doi:10.1371/journal.pone.0000997.g006
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Serum immunoglobulin titers were determined by enzyme-linked
immunosorbent assay (ELISA) using BD Falcon plates (BD
biosciences) coated with goat anti-mouse immunoglobulin
(2 mg/ml; Southern Biotechnology, Birmingham, AL) diluted in
sodium bicarbonate buffer (pH 8.2). Standard curves of each Ig
isotype were generated with purified mouse IgM, IgG1, IgG2a,
IgG2b and IgG3 (Southern Biotechnology). Plates were blocked
with 1% non-fat milk in PBS for 1 h at room temperature, and
sera were diluted in blocking buffer (1% non-fat milk in PBS) (IgM
and IgG1, 1:10,000; IgG2a, IgG2b and IgG3,1:5,000) and allowed
to bind to the plate for 2 hours at room temperature. Horseradish
isotype-specific antibodies (Southern Biotechnology) were then
added after washing with 0.05% Tween 20 in PBS and then
substrate Sigma Fast OPD (Sigma Aldrich, St. Louis, MO). Optical
densities at 490 nm were measured with a fluorescence plate reader
(SpectroMax 190, Molecular Devices, Toronto, Canada).
Flow cytometry
Single-cell suspensions were prepared from tibial bone marrow,
spleen and peritoneal cavity from mice euthanized with CO2.
Cells were suspended in RPMI 1640. Prior to staining, red cells in
spleens were lysed (BD Pharm Lyse, BD biosciences). Cells were
then suspended in PBS with 2% FBS and 1% sodium azide for
staining. Cells were surface stained for 30 minutes at 4
oC and
intracellular staining of BrdU is done following manufacturer (BD
Pharmingen) provided protocol. Cells were then suspended in
staining buffer and transferred for flow cytometry (BD LSR II, BD
biosciences). Analysis of the flow cytometry data was done with
Flowjo 7.2. Antibodies used were either purchased from BD
Pharmingen (La Jolla, CA): (B220, APC-Cy7 streptavidin, c-kit,
Sca-1, CD21, CD5, CD19, and Lin markers, CD3, Gr-1, CD11b,
Ter119) or purchased from EBioscience (La Jolla, CA), CD23 and
AA4.1.
Western blot
Cells were lysed by regular lysis buffer containing 1% Triton-
X100, 1:100 diluted, protein and phosphatase cocktails ( both
from Sigma). Nuclear and cytoplasmic proteins were isolated by
a nuclear and cytoplasmic protein extraction kit (Pierce Bio-
technology, Rockford, IL). Antibodies for western-blot are
phospho-antibodies of p-AKT, p-GSK3b, p-p38, p-p42/44, p-
JNK, p-IkB, p-p65, p-Stat3, and p-Stat-5, all from Cell Signaling,
and corresponding control antibodies of GSK3a/b,I kBa, from
Cell Signaling (Davers, MA), and those specific for p-65, and Sp1
from Santa Cruz Biotechnology (Santa Cruz, CA).
Electrophoresis mobility shift assay
Nuclear extracts were prepared as described previously [26]. 10-
mg aliquots of cell nuclear extracts were pre-incubated with 1 mgo f
poly(dI-dc) in binding buffer (10 mM Tris [pH 7.7], 50 mM
NaCl, 20% glycerol, 1 mM dithiothreitol [DTT], 0.5 mM EDTA)
for 10 min at room temperature. Approximately 1.5610
4 cpm of
32P-labeled DNA probes were then added and the reaction
proceeded for 30 min. The specificity of the binding was further
confirmed by anti-P65 or anti-P50 antibodies (Santa Cruz). The
sequence for the probe was 59-AGTTGAGGGGACTTTCC-
CAGGC-39. The sequence for the probe was 59-AGTTGAGGG-
GACTTTCCCAGGC-39. The complexes were resolved on a 5%
polyacrylamide gel in Tris-glycine buffer consisting of 25 mM
Tris, 190 mM glycine and 1 mM EDTA at room temperature.
The gel was dried at 80uC for 60 min and exposed to an X-ray
film.
NFkB activity reporter assay
Peritoneal cells extracted from WT and the Siglecg2/2 mice
were cultured in RPMI medium containing 10% FBS for
overnight. Next day, the cells were transfected with NF-kB
reporter plasmid of NF-kB-TA-luc (Clontech, San Diego, CA) by
using Lipofectamine 2000 in 10% FBS Opti-MEM medium for
16 hours, and recovered in fresh complete RPMI medium for
additional 12 to 16 hours. Plasmid Renilla luciferase (PRLSV40)
was used as internal control for monitoring transfection efficiency.
Bone marrow chimera
Bonemarrow cells fromWTandthe Siglecg2/2micewere mixed at
a 1:1 ratio (2.5610
6 each) and were injected into lethally irradiated
( 1 1 0 0R A D )W To rS i g l e c g
2/2 mice. The bone marrow, spleen,
lymph node and peritoneal lavages were harvested at 13 weeks after
irradiation and analyzed by flow cytometry.
In vivo treatment with IKK inhibitor
5-day old siglecG
2/2 mice were treated with 0.01 mg of IKK
inhibitor VI (Calbiochem, San Diego, CA) intra-peritoneally twice
daily for 8 days and spleen and peritoneal cavity cells were
harvested for analysis.
Statistics
The statistical significances of observed differences were analyzed by
student t-tests. *, 0.05.P.0.01; **, 0.01.P.0.001; ***, P,0.001.
SUPPORTING INFORMATION
Figure S1 Generation of Siglecg2/2 mice that expressed green
fluorescence protein (GFP) under the control of Siglecg regulatory
sequence. A. Diagram of construct (top), siglecg genomic structure
(middle) and the recombinant knock-out/in allele (bottom). Top,
diagram of the knock-out/in construct. LA, long arm that ended
before the Siglecg coding sequence in exon 2, SA, short arm
consisting of 1.8 kb intron 2 sequence. GFP coding sequence is
linked to exon 2 with its own stop codon and polyadenylations
sites. Neo sequence is transcribed from the opposite direction.
Middle, genomic structure, shaded area indicates coding sequence
from exon 2 to 12. Bottom, the structure of the knock-in allele.
The primers used are marked. B. Verification of homologous
recombination by PCR. Data shown were for clone 361, which
was used to generate the knockout/in mice. Integration of the
construction is confirmed by AT1/N1 primer pair, while
integration is confirmed by A1/N1, A2/N1 and A3/N1 pairs.
The AT1/AT2 pair was the positive control for PCR. The primer
sequences are: Primers used: A1: agctaagcacatgtgatggcta, A2:
aggtgaataagtataggcccggc, A3: tgtgtgacctcaaggttgctc, AT1: tca-
gagtctcacttaccactcc, AT2: tattcagaggagtctgtggc, N1: tgcgaggcca-
gaggccacttgtgtagc. C. Genotyping of the F2 mice using primers
that identify WT, heterozygous and homozygous knockout/in
mice. Primers used: siglecg-F: tcccagacttgcatgagaatc, silgecg-R:
atgttctctctggaccagagg, GFP-F: atgtgatcgcgcttctcgtt, GFP-R: gagcg-
caccatcttcttcaa. Product size: sigecg: 800bp, GFP: 280bp.
Found at: doi:10.1371/journal.pone.0000997.s001 (2.72 MB TIF)
Figure S2 Preferential proliferation of mature B1a cells does not
explain the expansion of B1a compartment in the Siglecg-deficient
mice. A. Proliferation of splenic B1 B cells of 2- (top) and 10
(bottom)-weeks old mice. B. Proliferation of peritoneal B1a B cells
from 10 week old mice. Two or 10 weeks-old Siglecg2/2 and
Siglecg+/+ mice were injected (ip) with 1 mg of BrdU 27 and
3 hours before sacrifice. Spleen and peritoneal B-1 a proliferation
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PLoS ONE | www.plosone.org 9 October 2007 | Issue 10 | e997is analyzed by BrdU incorporation. The gates used were shown in
the left. Profiles of BrdU incorporation is shown in the middle,
while the summary data are shown in the right. Data shown are
representative of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0000997.s002 (3.46 MB TIF)
Figure S3 Siglecg does not control apoptosis of the B1B cells.
Data shown are histograms depicting annexin V staining of ex vivo
splenic (A) or peritoneal B1a B cells of 10-week old mice. The gates
applied are the same as Fig. S2.
Found at: doi:10.1371/journal.pone.0000997.s003 (3.11 MB TIF)
Figure S4 No increase of B1a B cells in bone marrow in the
Siglecg2/2 mice.
Found at: doi:10.1371/journal.pone.0000997.s004 (0.92 MB TIF)
Figure S5 Siglecg-deficient bone marrow cells have competitive
disadvantages in reconstituting spleen B1 subsets in lethally
irradiated recipients. Spleen cells used were from chimera mice
described in Fig. 4 legends.
Found at: doi:10.1371/journal.pone.0000997.s005 (2.61 MB TIF)
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